NxStage Medical (NASDAQ:NXTM) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Volatility and Risk

NxStage Medical has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -4.12, indicating that its share price is 512% less volatile than the S&P 500.

Profitability

This table compares NxStage Medical and ENDRA Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NxStage Medical -3.67% -7.02% -4.61%
ENDRA Life Sciences -114.33% -394.07% -266.99%

Institutional and Insider Ownership

83.2% of NxStage Medical shares are owned by institutional investors. Comparatively, 4.8% of ENDRA Life Sciences shares are owned by institutional investors. 4.9% of NxStage Medical shares are owned by insiders. Comparatively, 12.7% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares NxStage Medical and ENDRA Life Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NxStage Medical $393.94 million 4.82 -$14.47 million ($0.22) -131.73
ENDRA Life Sciences $350,000.00 66.79 -$5.37 million N/A N/A

ENDRA Life Sciences has lower revenue, but higher earnings than NxStage Medical.

Analyst Ratings

This is a summary of recent ratings and price targets for NxStage Medical and ENDRA Life Sciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NxStage Medical 0 0 0 0 N/A
ENDRA Life Sciences 0 0 0 0 N/A

Summary

NxStage Medical beats ENDRA Life Sciences on 6 of the 9 factors compared between the two stocks.

About NxStage Medical

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound systems. It offers diagnostic imaging technologies, such as CT, MRI, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease or internal bleeding. It also offers the Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.